Q1 2026 consolidated revenue 71.18B won (+18.2% YoY), operating profit 9.38B won (+77.7%), net income 7.47B won (+45.8%).
Debt-free: debt ratio 13.6%, cash & equivalents 56.28B won (separate), very stable financial structure.
Reaffirmed 300 won per share year-end cash dividend; remaining treasury shares (116,120 shares) to be used for employee incentives over 3 years, no new buyback or cancellation.
Contingent liability: 50B won lawsuit against National Health Insurance Service over contract invalidity (choline alfoscerate) pending at appellate court.
R&D expense 4.34B won (6.1% of sales); Alzheimer's improved new drug WIL-1901 in GMP production, depression improved new drug WIP-2401 under approval application.
Subsidiary AsYou (distribution) posted net loss of 1.01B won in Q1; equity-method loss from Bifido of 0.44B won.
Change of largest shareholder in Oct 2025 via gift from Lee Gwang-sik to Lee Won-beom (13.27%).